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Background:Microglia activation contributes to chronic pain and to the adverse effects
of opiate use such as analgesic tolerance and opioid-induced hyperalgesia. Both mu
opioid receptor (MOR) encoded by Oprm1/OPRM1 gene and toll like receptor 4 (TLR4)
have been reported to mediate these morphine effects and a current question is whether
microglia express the Oprm1 transcript and MOR protein. The aim of this study was to
characterize Oprm1-MOR expression in naive murine and human microglia, combining
transcriptomics datasets previously published by other groups with our own imaging
study using the Cx3cr1-eGFP-MOR-mCherry reporter mouse line.
Methods: We analyzed microglial Oprm1/OPRM1 expression obtained from
transcriptomics datasets, focusing on ex vivo studies from adult wild-type animals and
adult post-mortem human cerebral cortex. Oprm1, as well as co-regulated gene sets
were examined. The expression of MOR inmicroglia was also investigated using our novel
fluorescent Cx3cr1-eGFP-MOR-mcherry reporter mouse line. We determined whether
CX3cR1-eGFP positive microglial cells expressed MOR-mCherry protein by imaging
various brain areas including the Frontal Cortex, Nucleus Accumbens, Ventral Tegmental
Area, Central Amygdala, and Periaqueductal Gray matter, as well as spinal cord.
Results: Oprm1 expression was found in all 12 microglia datasets from
mouse whole brain, in 7 out of 8 from cerebral cortex, 3 out of 4 from
hippocampus, 1 out of 1 from striatum, and 4 out of 5 from mouse or rat
spinal cord. OPRM1 was expressed in 16 out of 17 microglia transcriptomes
from human cerebral cortex. In Cx3cr1-eGFP-MOR-mCherry mice, the
percentage of MOR-positive microglial cells ranged between 35.4 and 51.6%
in the different brain areas, and between 36.8 and 42.4% in the spinal cord.
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Conclusion: The comparative analysis of the microglia transcriptomes indicates that
Oprm1/OPRM1 transcripts are expressed in microglia. The investigation of Cx3cr1-
eGFP-MOR-mCherry mice also shows microglial expression of MOR proteinin the brain
and spine. These results corroborate functional studies showing the actions of MOR
agonists on microglia and suppression of these effects by MOR-selective antagonists or
MOR knockdown.
Keywords: microglia, opioid receptor, mu, transcriptomics, gene clusters, fluorescent reporter mice, analgesic
tolerance, opioid-induced hyperalgesia
INTRODUCTION
Activation of the mu opioid receptor (MOR), encoded by the
Oprm1/OPRM1 gene in rodents and humans, respectively (1, 2),
mediates opioid analgesia and the adverse consequences of opioid
use (3, 4). Glial cells and in particular microglia are known to
contribute to chronic pain (5) as well as to opioid tolerance
and opioid-induced hyperalgesia (OIH) (6–8). However, whether
microglia express Oprm1 and whether microglial Oprm1 would
have a role in chronic pain and other opioid effects remains
to be demonstrated. Most studies reporting MOR expression
or function in microglia have been performed on cultured
microglia (9–18). It has been shown however that gene expression
profiles differ between microglia in culture and adult mouse
microglia in vivo (19) and therefore the demonstration of MOR
expression in cultured microglia does not allow to conclude
for MOR expression in adult microglia in vivo. Horvath et al.
(20) have shown MOR expression in rat spinal microglia in
vivo by immunohistochemistry. However, two other studies
have contradicted these findings by showing a lack of MOR
expression in spinal cord microglia (21, 22). Thus, whether
microglia in adults express MOR still remains an unsolved
question. Specifically, Corder et al. present considerable evidence
that argues against the expression of MOR messenger and
protein inmouse spinal cordmicroglia. Their findings are further
strengthened by transcriptomic analyses which show a lack in
co-expression of Oprm1 mRNA with microglial markers (21).
However, critical analysis and commentary on these interesting
results is not possible yet due to the limited access of the
datasets used for transcriptomic analysis. Therefore, whether
Oprm1/OPRM1 are expressed by microglia remains a matter of
debate that should be further investigated. To date, there are
no published studies focusing on the analysis of a large series
of transcriptomic datasets for Oprm1 expression in microglia
that would allow assessing, unambiguously, Oprm1 expression
in microglia in vivo. In addition, OPRM1/MOR expression in
humanmicroglia is yet to be fully characterized. For this purpose,
we have used novel approaches to characterize Oprm1/OPRM1
Abbreviations: BDNF, brain-derived neurotrophic factor; CeA, central amygdala;
CTAP, D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2; eGFP, enhanced green
fluorescent protein; FCx, frontal cortex; KO, knockout; MA, microarray; Mars-
seq, massively parallel Single-cell RNA-seq; MOR, mu opioid receptor; NAcc,
nucleus accumbens; OIH, opioid-induced hyperalgesia; PAG, periaqueductal gray;
PBS, phosphate buffer baline; PFA, paraformaldehyde; RNA-seq, RNA-sequencing;
TLR, toll like receptor; VTA, ventral tegmental area.
expression in microglia based on transcriptomics and have used
fluorescent reportermice to characterizeMOR expression in vivo.
A number of laboratories have generated transcriptomics
datasets for microglia that can be used for analyzing gene
expression profiles (23, 24) as well as for investigating microglia
physiology and their responses in disease (25, 26). We have
analyzed published datasets from microarray (MA) and RNA-
sequencing (RNA-seq) studies performed on rodent and human
microglia for Oprm1 and OPRM1 gene expression. We have
completed this analysis by imaging microglial MOR using a
novel double fluorescent Cx3cr1-eGFP-MOR-mCherry mouse
line. The chemokine receptor CX3CR1 is a specific marker
for phagocytic cells and labels specifically microglia and
macrophages in the nervous system of naive animals (27–29).
The Cx3cr1-eGFP mouse line was originally used to explore
CX3CR1 function (30) then later to map the fate of tissue
macrophages including microglia (28, 29). A reporter knock-in
mouse line for MOR, the MOR-mCherry line, allows to map the
distribution of MOR-expressing cells in mice using fluorescence
imaging (31). In order to localize MOR protein in microglia,
we have bred these two lines together to generate the Cx3cr1-
eGFP-MOR-mCherry mouse line. Thus, we have analyzed MOR
expression in various brain regions implicated in chronic pain
or chronic opiate effects as well as the spinal cord in control
non-pathological conditions. In addition, as sex differences are
an important factor for chronic pain (32–34) and greatly impact
the microglial contribution to pain (35, 36), we investigated
Oprm1/OPRM1-MOR presence in microglia from both females
and males.
MATERIALS AND METHODS
Transcriptomics Analyses
As microglia develop after birth until post-natal day 15,
followed by stabilization of microglial numbers (37–39),
we focused the Oprm1 expression analysis on microglia
from juvenile-adult wild-type naïve rodent and juvenile-adult
humans with no reported pain phenotype. The datasets
used and related information including the pathology of
patients from whom microglia were collected, are indicated
in Supplementary Tables 1–4. The selection criteria for which
datasets to include in the present study were as follows:
normalized mouse datasets included in the database recently
published by Friedman et al. (40) (see Data S2 in Friedman
et al.) and additional normalized datasets containing Oprm1
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in their gene list; from wild-type mice aged 0.5 months and
older. Microglia datasets from mouse whole brain were from
the studies by Wang et al. (41), Verheijden et al. (42), Poliani
et al. (43), Erny et al. (44), Szulzewsky et al. (45), Pyonteck
et al. (46), Bruttger et al. (47), Lavin et al. (48), Bennett et al.
(49), Gosselin et al. (50), Krasemann et al. (51), and Zhao et al.
(52). Microglia datasets from mouse brain areas were from Orre
et al. (53), Arumugan et al. (54), Grabert et al. (55), Friedman
et al. (40), Srinivasan et al. (56), Zhang et al. 2014 (57), and
Matcovitch-Natan et al. (58). Microglia datasets from rodent
spinal cord were from Chiu et al. (59), Denk et al. (60), Noristani
et al. (61), Matcovitch-Natan et al. (58), and Jokinen et al. (62).
Information on these datasets including publication authors and
year, accession number, mouse or rat strain, sex, age, dissociation,
andmicroglia isolation methods, and genomics assay are given in
Supplementary Tables 1–4.
Human datasets comprised those published by Zhang et al.
(63) and contained in Friedman’s Supplementary Table 2 as well
as normalized datasets recently reported by Gosselin et al. (64)
and Galatro et al. (65) as described in Supplementary Table 4.
Normal cortical regions were resected from patients with diseases
described in column F. Among the 19 datasets by Gosselin
et al. we selected 10 datasets derived from individuals aged
13 and older. Among the 39 datasets from adult individuals
by Galatro et al. we selected 8 datasets derived from samples
collected at a maximum delay of 10 h post-mortem. Information
on these datasets including publication authors and year,
accession number, sex, age, cortex area, dissociation, and
microglia isolation methods, and genomics assay are given in
Supplementary Table 4.
In addition to our main focus set, (A) showing only
the expression levels of Oprm1 gene transcript from purified
microglia, three other groups of gene clusters were formed:
(B) Myeloid cells, (C) Activation patterns and (D) Neurons
and Astrocytes. The list of genes contained in each of
the gene clusters of B, C, and D was formed using the
gene lists defined in Friedman et al. (40) and filtered to
exclude the few genes expressed by any other cell type.
The Myeloid gene clusters (B) include the Microglia, the
Macrophage, and the Neutrophil-Monocytes gene clusters,
respectively. The activation pattern clusters (C) comprise
the Interferon-related, Proliferation-related, LPS-related and
Neurodegeneration-related gene clusters. The Neurons and
Astrocyte gene clusters (D) are composed of the Neuron-
associated, Excitatory neuron-associated, GABAergic neuron-
associated, and Astrocyte-associated genes clusters.
The logarithm scale two (log2) transformation was applied to
each data sample values and 1 was added to expression values to
avoid indetermination for zero count reads. For each data sample,
the first (25th percentile), the second (median), and the third
quantile (75th percentile) values were computed. The log2 values
for the Oprm1 transcript were also obtained for each dataset.
The log2 values associated with each gene subset of B, C, and
D categories were isolated for each sample and an average value
was calculated for each subset. The R environment (version 3.5.0)
was used to create the basic figures. The vioplot R package was
used to obtain a violin plot like contour for the log2 values of
each data sample. The log2 values and the 25th, 75th percentile
and median values were superimposed on the violin plots using
different colors as shown in Figures 1–4.
For determining correlations between Oprm1/OPRM1
expression and the expression of the gene clusters described
above, z-scores transformations (1+log2 values) were calculated
from the mean expression level of each cluster for each dataset
included in the study. The Orre et al. (53) mouse cortex dataset
and the S037 dataset of the Gosselin et al. study (64) were
removed from the analysis as they varied substantially from all
other datasets within their group. The correlation analysis for
human datasets included all dataset except for S037 set.
Cx3cr1-eGFP-MOR-mCherry Mouse Line
Animals and Ethics Statement
The animals were housed under standard light, temperature, and
humidity conditions (12 h light-dark cycle, 21 ± 1 ◦C, 55 ± 10%
humidity) with food and water ad libitum. Brains and spinal
cords were collected from male and female mice aged between
5 and 15 weeks. All experiments were conducted respecting the
European Communities Council Directives of 22 September 2010
(directive 2010/63/UE) under the guidelines of the Committee
for Research and Ethical issues of IASP published in PAIN, 1983;
16:109-110, and were approved by the local ethical committee
(Com’Eth d’Ethique pour l’Expérimentation Animale IGBMC-
ICS, license N◦17) with the agreement number 00876-02.
Cx3cr1-eGFP-MOR-mCherry Mice
The Cx3cr1-eGFP-MOR-mCherry mouse line was generated
by crossing Cx3Cr1-eGFP mice (29) and MOR-mCherry
mice (31) to obtain viable heterozygous animals. These were
intercrossed to generate homozygous Cx3Cr1-eGFP-MOR-
mCherry mice that are fertile and develop normally. Genotyping
was performed by PCR to detect both Cx3Cr1-GFP sequence
(35 cycles at 94◦C for 30 s, 65.5◦C for 30 s, and 72◦C for
2min) using the following primer sequences: Cx3Cr1-Fwd: 5′-
TTCACGTTCGGTCTGGTGGGAAATC-3′, Cx3Cr1- Rev:
5′-TTCCTAGTGGAGCTAGGGTCGGGG-3′, eGFP-Fwd:
5′-GATCACTCTCGGCATGGACG-3′, and MOR-mCherry
sequence (35 cycles at 94◦C for 1min, 63◦C for 1min, and
72◦C for 1min) using a forward primer located on exon four of
Oprm1 gene, -Fwd: 5′-TGACGTGACATGCAGTTGAGATTT-
3′and a reverse primer located in the 3’ UTR region, Rev: 5′-
TCCCACAAACCCTGACAGCAAC-3′. Both female and male
Cx3cr1-eGFP-MOR-mCherry mice were analyzed for MOR
expression in microglia (3 animals per sex).
Tissue Preparation
Mice were deeply anesthetized with intraperitoneal
administration of 100/5 mg/kg ketamine/xylazine (Virbac,
Carros, France; Rompun, Bayer, La Garenne Colombes, France)
and were intracardially perfused with 4% Paraformaldehyde
(PFA) in Phosphate Buffer Saline (PBS) solution (4%PFA/PBS).
The whole brain and spinal cord were isolated and post-fixed
overnight at 4◦C in 4%PFA/PBS. Samples were rinsed three
times in PBS and cryoprotected in a sucrose/PBS gradient (10,
20, and 30%) for 24 h each. Tissues were embedded in OCT
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FIGURE 1 | Oprm1 and gene clusters expression in mouse whole brain microglia datasets. Expression levels of the genes identified in each dataset are represented in
violin plots demonstrating the median, as well as the 25th and 75th quartiles. Datasets are represented by name of the first author in (A), which are denoted
numerically in (B–D). (A) Expression of Oprm1 is below the median in purified microglia assayed with MA, and fluctuates above and below the median in purified
microglia assayed with RNA-seq. (B) Expression values of the Myeloid cell clusters demonstrate a high expression of Microglia-related genes which are in the 75th
quartile in all the datasets analyzed. (C) Expression values of the Activation pattern clusters are below the 75th quartile in all but one dataset (dataset #6). (D)
Expression values of the Neurons and Astrocytes clusters are below the median in 5 out 6 of the datasets derived from MA assays, whereby the Astrocyte-related
genes have expression values above the 75th quartile in dataset #5. When assayed with RNA-seq, the Astrocyte-related genes are below the median, except for
dataset #12, where the values are above the median.
(Tissue Tek, Sakura Fine Technical, Torrance) and coronally
(brain) or transversally (spinal cord) sectioned at 30µm on
Superfrost microscope slides using a cryostat (Leica CM3050S).
Cryosections were dried at room temperature and then stored at
−20◦C before imaging.
Immunohistochemistry and Quantifications
For immunohistochemistry, cryosections were rehydrated with
PBS and were then incubated in a blocking solution (10% horse
serum/0.1% Triton X-100/PBS) for 30min at room temperature.
The sections were incubated with the primary antibodies diluted
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FIGURE 2 | Oprm1 and gene clusters expression in mouse cortex, hippocampus and striatum microglia datasets. Expression levels of the genes identified in each
dataset are represented in violin plots demonstrating the median, as well as the 25th and 75th quartiles. Datasets are represented by name of the first author in (A)
which are denoted numerically in (B–D). In mouse cortex and hippocampus, microglia were assayed with either microarrays (MA) or RNA-sequencing (RNA-seq) as
underlined on (A) and assayed with MA only in the striatum (dataset #13). (A) Oprm1 expression values were distributed below and above the median independent of
the assay used to measure gene expression. RNA-seq datasets (#8 and 12) yielded to no expression of Oprm1 in microglia. The highest Oprm1 expression value was
yielded by dataset #1 in cortical microglia. (B) Among the Myeloid gene clusters, the Microglia-related gene module was the mostly highly expressed in all datasets
analyzed, with expression values distributed about the 75th quantile. (C) Proliferation-related genes were the most highly expressed within the Activation pattern
clusters, distributed within the 75th quantile. (D) Neuron-, GABAergic-, and Astrocyte-related genes had expression values that were below the median in most of the
datasets analyzed. In the cortex and hippocampus, the Excitatory neuron- and Astrocyte-related genes are distributed along the median for datasets #5–7 and #10,
11.
in 10% normal horse serum/0.1% Triton X-100/PBS overnight at
4◦C. The sections were then washed 3 times in 0.1% Triton X-
100/PBS and incubated with secondary antibodies and Hoechst
for 1 h at room temperature, in the same solution as the primary
antibodies. After washing 3 times in 0.1% Triton/PBS and once
in PBS alone, slides were mounted with the S3023 aqueous
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FIGURE 3 | Oprm1 and gene clusters expression in rodent spinal cord
microglia datasets. Expression levels of the genes identified in each dataset
are represented in violin plots demonstrating the median, as well as the 25th
and 75th quartiles. Datasets are represented by name of the first author in (A)
which are denoted numerically in (B–D). Gene expression in the spinal cord
was assayed with RNA-seq exclusively. (A) Oprm1 expression values ranged
from above the median to undetected level (#4). (B) In the Myeloid gene
cluster, the Microglia- related genes were the mostly highly expressed in all
datasets analyzed, with expression values distributed about the 75th quantile.
(C) Proliferation-related genes were the most highly expressed within the
Activation pattern clusters, except in dataset#5, which had higher expression
values for the LPS module in microglia purified from rat. Overall, the expression
values of Activation patterns gene clusters were low compared to the
Microglia-related genes. (D) Neuron-, GABAergic- and Astrocyte-related genes
had expression values that were low compared to the Microglia-related genes
except for dataset #2 that show high Astrocyte-related module expression (B).
mounting medium (DAKO). For staining cis-Golgi, trans-Glogi,
and lysosomes, the rabbit polyclonal anti-GM130 antibody
(11308-1-AP, Proteintech), the rabbit polyclonal anti-TGN38
antibody (NBP1-03495, Interchim), and the mouse monoclonal
anti-Lamp1 antibody (H4A3, Developmental Studies Hybridoma
Bank DSHB) were used. The optimal dilutions were set up in
preliminary experiments. Anti-GM130, anti-TGN38, and anti-
Lamp1 were used at dilutions 1:500, 1:200, and 1:200 (0.6, 5,
0.1µg/ml), respectively. The secondary antibodies used were
the Cy5 conjugated donkey anti-mouse (1:1,000, 715-176-150,
Jackson) and the Cy5 conjugated donkey anti-rabbit (1:500,
711-176-152, Jackson) Ig antibodies. Images were acquired with
a confocal microscope (8UV, Leica Microsystem) using a 40x
objective. The FIJI package for ImageJ software was used for
image analysis (66). The percent of MOR-positive microglia
among the CX3CR1-eGFP-positive microglia in the different
brain and spinal cord regions were quantified on multiple
microscopic fields from 3 female and 3 male adult animals. The
number of fields counted and of cells examined are indicated in
the Supplementary Table 5.
Statistical Analysis
Statistical analyses were performed with GraphPad Prism version
6.01 to investigate the correlations between Oprm1 expression
and the different clusters mentioned above, as well as to compare
MOR expression in CX3CR1-eGFP-positive microglia between
male and female mice. Oprm1 and gene module z-scores were
all non-normally distributed and correlations were assessed with
the Spearman’s correlation test. The mean percentage of MOR-
positive and CX3CR1-eGFP-positive microglia were tested for
normality as well and compared using the Unpaired Student’s
t-test or Mann Whitney test where applicable. The results
are presented as the mean ± SEM for microglia cell counts
(percentages). A p-value of 0.05 or less was considered to be
statistical significant.
RESULTS
Oprm1/OPRM1 Expression in Rodent and
Human Microglia Transcriptomics Datasets
Microglia From Mouse Whole Brain
Oprm1 was expressed in the twelve datasets analyzed
(Figure 1A). Among those, six were issued from MA, see
references (41–46) and six from RNA-seq, see references
(47–52), as described in Supplementary Table 1. Oprm1 levels
ranged from above the median (n = 4) to between the median
and first quartile (n = 4) and below the first quartile (n = 4).
Oprm1 expression tended to be more homogenous in MA
than in RNA-seq datasets. The Myeloid gene modules defined
by Friedman et al. (40) included Microglia, Macrophage, and
Monocyte-neutrophil gene clusters. The Microglia gene cluster
was highly expressed in all datasets, at the highest level of all gene
clusters (Figure 1B). Macrophage and Neutrophil-monocyte
cluster expression was distributed over and under the median
among datasets (Figure 1B). The Proliferation cluster stood out
as the most expressed among the Activation pattern gene sets,
followed by the LPS, or Interferon and then Neurodegeneration
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FIGURE 4 | Oprm1 and gene clusters expression in human cortex microglia datasets. Expression levels of the genes identified in each dataset are represented in
violin plots demonstrating the median, as well as the 25th and 75th quartiles. In all datasets, microglia were assayed with RNA-seq. Gosselin datasets (#2–9)
comprised of microglia isolated from young males and females, while the other human datasets were from adult and aged postmortem samples of unknown gender
(#1) or exclusively males (10–17). Datasets are represented by name of the first author (A), which are denoted numerically in (B–D). (A) Oprm1 expression values were
distributed below or along the median in the Zhang and Gosselin datasets (#1 and 2–9) but consistently below the median in all the Galatro datasets. (B) In the
Myeloid gene clusters, the Microglia- related genes were the most highly expressed in all datasets analyzed, with expression values distributed above the 75th
quantile, except in dataset #17 which had higher expression values for the Monocytes-Neutrophils-related genes. (C) Activation pattern gene clusters were highly
expressed in purified human microglia, distributed within, and above the 75th quantile. The majority of the datasets reported the highest expression values for the
LPS-related genes. Interferon-related genes had the highest expression values in the datasets #5, 10, 14, and 16 with causes of death associated with blood
circulation and aneurysm. (D) Neuron-, GABAergic-, and Astrocyte-related genes had expression values along and below the median in dataset#1 and those provided
by Gosselin (#2–9). Expression values were all below the median in the aged samples (#10–17).
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gene sets (Figure 1C). The three neuronal (Neurons, Excitatory
and GABAergic) gene sets were positioned below the median
in nine of the datasets (Figure 1D). The Astrocyte cluster was
below the median in eight of the datasets (Figure 1D).
Microglia From Murine Cortex, Hippocampus, and
Striatum
In the cortex, Oprm1 expression was expressed in seven out of
the eight datasets generated by either MA (53–55) or RNAseq
(40, 56, 57) and not detected in the dataset by Matcovitch-
Natan et al. derived from Massively parallel Single-cell RNA-
seq (Mars-seq) (58). Expression ranged from above the median
in two datasets, between median, and first quartile in three
datasets, below the first quartile in two datasets, to not being
expressed in the Mars-seq dataset (Figure 2A). The dataset with
very highOprm1 expression was generated using the Agilent MA
technology (53) while Affymetrix arrays were used in the other
MA studies. In the hippocampus, Oprm1 was above the median
in one dataset, ranged between the median, and first quartile
in two datasets, but not expressed in the Mars-seq dataset. In
the striatum dataset by Grabert et al., the Oprm1 was above
the first quartile. The Microglia gene cluster was also highly
expressed and the highest in all datasets (Figure 2B), similarly
to whole mouse brain datasets. Macrophage and Neutrophil-
monocyte module expression ranged among datasets from over
to under the median, with the Macrophage cluster higher than
that of Neutrophil-monocyte (Figure 2B). The Proliferation
cluster stood out as the most expressed among the Activation
pattern gene sets, followed by the LPS or Interferon and then
Neurodegeneration gene sets (Figure 2C), comparably whole
mouse brain data. The neuronal (Neurons, Excitatory and
GABAergic) as well as the Astrocyte gene set were positioned
below the median in nine of the datasets (Figure 2D).
Rodent Spinal Cord
The expression ofOprm1was analyzed in four mouse and one rat
spinal microglia datasets obtained by RNA-seq (58–62). Oprm1
is expressed above the median in two mouse spinal cord datasets,
below the first quartile in one data set, and not expressed in the
Mars-seq dataset by Matcovitch-Natan et al. The rat spinal cord
dataset showed Oprm1 level above the first quartile (Figure 3A).
The Microglia gene cluster was also highly expressed in the
five datasets (Figure 3B). Macrophage and Neutrophil-monocyte
cluster expression varied among datasets from over to below the
median (Figure 3B). In the Activation pattern gene modules, the
Proliferation gene sets were the most expressed in mouse but
not rat, whereas Neurodegeneration gene sets showed the lowest
level (Figure 3C), similarly to what was found in mouse brain.
The three neuronal (Neurons, Excitatory and GABAergic) gene
sets were positioned below or at the median level while Astrocyte
cluster expression differed across the datasets (Figure 3D).
Human Cortex
OPRM1 level was analyzed in microglia RNA-seq datasets
generated from temporal cortex gray matter (63), different
cortical areas (64), and parietal cortex (65) (Figure 4A). OPRM1
is expressed above the median in the dataset generated by Zhang
et al. (63) for which microglia were purified from cortex gray
matter collected on juvenile-adult individuals. In the study by
Gosselin et al. (64) on cortical microglia enriched from young
adults, OPRM1 levels ranged between the median and first
quartile. In the S037 dataset issued frommicroglia collected from
a brain tumor, OPRM1 was highly expressed. In the microglia
datasets by Galatro et al. (65), collected from the parietal cortex
of aged people (57–102 years), OPRM1 was around the first
quartile and not expressed in the S12067 sample (Figure 4A).
The Microglia gene module was the most expressed in all sets
except one and the Macrophage cluster had generally a higher
level than the Neutrophil-monocyte cluster (Figure 4B). Among
the activation pattern gene sets, the LPS and Interferon sets
showed mostly the highest levels, followed by the Proliferation
cluster. The Neurodegeneration gene sets showed the lowest
level of expression (Figure 4C). The values for the Excitatory
and GABAergic clusters were higher than those of the Neurons
cluster, which showed the lowest expression levels (Figure 4D),
differing from mouse datasets. The Astrocyte cluster was below
the median on most datasets (Figure 4D).
Single Cell RNAseq Data Sets
We investigated Oprm1 expression in microglia datasets from
published single cell RNA-seq studies. Transcripts for Oprm1
were not found in the datasets which contained about 1,300,
1,985, 6,000, 1,179, 1,900–3,300, and 1,169 and 800 genes
expressed per cell, respectively (27, 67–72). Microglia datasets
generated from microdissected basal ganglia nuclei led to the
identification of 2,647 expressed genes per cell that did not
include Oprm1 (73).
Relationships Between Oprm1 Expression
and Gene Clusters
Myeloid Cells
We investigated the relationships betweenOprm1 expression and
the expression of myeloid molecular signatures (modules) that
are genes found to be co-expressed in the study by Friedman
et al. (40). Microglia, in comparison with Macrophages cluster,
had inverse trends regarding their correlations with Oprm1
in the rodent analyses (Figures 5–9). The Microglia module
was positively correlated with Oprm1 (mouse cortex, mouse
hippocampus, and rodent spinal cord), while the Macrophage
cluster was negatively correlated with Oprm1.
In whole brain analysis, Oprm1 expression had a negative
correlation with the Macrophage and Monocyte-neutrophil
clusters, which was statistically significant with the Macrophage
gene cluster only (p = 0.030). In the mouse cortex, there was
a strong positive correlation between Oprm1 and the Microglia
gene set which was statistically significant only for this cluster
(r = 0.955; p = 0.0032) but not for the other myeloid sets
(Figure 6). No significant correlation was found between the
Monocyte-neutrophil gene cluster and any dataset (Figures 5–8).
Activation Patterns
We investigated the relationships between the expression of
Oprm1 and of the myeloid activation modules as described (40).
There was a negative correlation between Oprm1 and the LPS
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FIGURE 5 | Correlation of Oprm1 gene expression within the Myeloid cells, Activation patterns, and Neurons and Astrocytes gene clusters in mouse whole brain
datasets. Oprm1 expression does not correlate with the microglia-related and the Monocyte-Neutrophil-related genes (p >0.05, ns) but is significantly negatively
correlated with the Macrophages-related genes (r = 0.636; *p = 0.03). Oprm1 expression has a negative correlation (r < 0) with all the Activation patterns-, Neurons,
and Astrocytes gene clusters, which is only statistically significant for the LPS-related gene module (*p = 0.014). All correlations were determined with the Spearman’s
correlation test.
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FIGURE 6 | Correlation of Oprm1 gene expression within the Myeloid cells, Activation patterns, and Neurons and Astrocytes gene clusters in mouse cortex datasets.
Oprm1 expression is positively and significantly correlated with the microglia-related genes (r = 0.955; **p = 0.0032) but does not correlate with the Macrophages-
and Monocyte-Neutrophils-related genes (r ≤ 0.214; p > 0.05, ns). Oprm1 expression does not correlate with any of the Activation patterns- (r < 0; p > 0.05, ns),
Neurons or Astrocytes gene clusters (r ≤ 0.09; p > 0.05, ns). All correlations were determined with the Spearman’s correlation test.
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FIGURE 7 | Correlation of Oprm1 gene expression within the Myeloid cells, Activation patterns and Neurons and Astrocytes gene clusters in mouse hippocampus
datasets. There is no correlation between Oprm1 expression and all the gene clusters investigated in the mouse hippocampus datasets (p > 0.05, ns). Although
Oprm1 expression seems to have a strongly positive correlation with the Neurons and Astrocytes gene clusters (r = 1 and r = 0.800, respectively) this is not
statistically significant (p > 0.05, ns). All correlations were determined with the Spearman’s correlation test.
Frontiers in Psychiatry | www.frontiersin.org 11 January 2019 | Volume 9 | Article 726
Maduna et al. Microglia Express Mu Opioid Receptor
FIGURE 8 | Correlation of Oprm1 gene expression within the Myeloid cells, Activation patterns, and Neurons and Astrocytes gene clusters in rodent spinal cord
datasets. Oprm1 expression has a positive correlation (r = 0.700) with the Microglia-related genes but which is not statistically significant (p > 0.05, ns). Oprm1
expression is negatively correlated (r < 0) with Macrophages, Monocytes-Neutrophils- related genes, and Activation patterns gene clusters, but this is not statistically
significant (r < 0; p > 0.05, ns). Oprm1 expression has a positive correlation with the Neurons (r > 0.5) which is not statistically significant (p > 0.05, ns). There is no
correlation between Oprm1 expression and Astrocytes gene clusters (r = 0.2; p = 0.783, ns). All correlations were determined with the Spearman’s correlation test.
Frontiers in Psychiatry | www.frontiersin.org 12 January 2019 | Volume 9 | Article 726
Maduna et al. Microglia Express Mu Opioid Receptor
FIGURE 9 | Correlation of Oprm1 gene expression within the Myeloid cells, Activation patterns and Neurons and Astrocytes gene clusters in human cortex datasets.
Oprm1 expression had a negative correlation with Microglia- and Macrophage-related genes (r < 0) and a positive correlation with the Monocytes-Neutrophils-related
genes which were not statistically significant (p > 0.05; ns). Within the Activation patterns-related genes, Oprm1 expression has a weak positive correlation (r < 0.5)
which is not statistically significant for the LPS-related genes (p > 0.5). There is a statistically significant positive correlation between Oprm1 expression and the
Proliferation-related genes (r = 0.741; **p = 0.002). There is a statistically significant positive correlation between Oprm1 expression and the GABAergic- (r > 0.5;
***p = 0.0006), Neurons-, and Astrocytes-related genes (r > 0.5; ****p < 0.0001).
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gene cluster in the mouse whole brain datasets (Figure 5) and
a positive correlation between OPRM1 and the Proliferation-
related gene level for the human cortex datatsets (Figure 9). No
correlation was found between Oprm1 level and the Interferon
cluster in any of the dataset studied (Figures 5–9).
Neurons and Astrocytes
The analysis for relationships between Oprm1 expression and
expression of the Neuron and GABAergic neuronal signatures
indicated no correlation between Oprm1 and these modules for
whole mouse brain, cortex, hippocampus, and rodent spinal cord
datasets (Figures 5–8). The p and r values obtained from the
analysis of hippocampus and spinal cord data suggest that more
datasets are required to increase the power of the correlation
analysis. For the human cortex datasets, a positive correlation was
found betweenOprm1 expression and expression of the Neuronal
and Astrocyte gene modules (Figure 9).
MOR Expression in CX3cr1-eGFP Microglia
MOR Expression in Brain and Spinal Cord
The Figures 10, 11 show that Cx3cr1-eGFP-positive cells
display the typical microglia morphology with no neuronal,
astrocytic or lymphocytic shapes, confirming previous findings
on colocalization of CX3CR1-eGFP with the CD11b or Iba-
1 microglia and macrophage markers (37, 74, 75) but not
neuronal, astrocytic, or oligodendrocytic markers (76, 77) in
the brain. MOR is expressed in microglia of different brain
regions in female and male Cx3cr1-eGFP-MOR-mCherry mice,
in the Frontal Cortex (FCx), Nucleus Accumbens (NAcc),
Central Amygdala (CeA), Ventral Tegmental Area (VTA),
and Periaqueductal Gray (PAG) (Figure 10). The percent of
microglia expressing MOR-mCherry protein ranges from 35.4
± 4.1 to 51.6 ± 3.5 (Supplementary Table 5). The percentage
of MOR-positive microglia was calculated in the FCx, NAcc,
CeA, and PAG of female and male brains. The VTA showed
a lower percentage of microglia containing MOR in females
than in males which was statistically significant (p = 0.0037)
(Supplementary Table 5).
In spinal cord dorsal horn, MOR is expressed in
microglia of both female and male Cx3cr1-eGFP-MOR-
mCherry mice (Figures 11A,B, Supplementary Video 1,
Supplementary Table 5). The percentage of microglia expressing
MOR ranged from 37.1 ± 2.7 to 44.5 42.4 ± 2.6 in cervical,
thoracic and lumbar segments, with no statistical difference
between the segments (Supplementary Table 5). There were
no statistically significant differences in the percentages of
MOR-expressing microglia between males and females with 36.9
± 2.3% and 36 ± 2.4%, 38.8 ± 2.1% and 42.4 ± 2.5%, and 37.1
± 2.7% and 39.5 ± 2.3% in cervical, thoracic, and lumbar spinal
segments, respectively (Supplementary Table 5).
MOR-Golgi-lysosome Localization
To specifically localize MOR within the intracellular
compartments of spinal microglia, we labeled Cis-Golgi,
trans-Golgi, and lysosomes with GM130, TGN38, and Lamp1
antibodies, respectively. Microglial MOR co-localized with
GM-130 (Figure 11C) and TGN38 (Figure 11D) but not
with Lamp1 (Figure 11E). Together, this indicates that
microglial MOR is localized in cis and trans-Golgi rather than
lysosomes.
DISCUSSION
Altogether the transcriptomics and imaging data show MOR
expression in microglia of all analyzed mammalian brain areas
and the spinal cord. The expression of Oprm1 transcripts
and MOR protein in microglia was shown previously by
using RT-qPCR or antibody based techniques, respectively (9–
14, 16). Although two papers found no expression of MOR
in microglia by using the same above-mentioned techniques
(21, 22), a link between microglial activation and MOR
expression and function was demonstrated, mostly in in
vitro studies on murine primary microglia cultures. Low
concentrations of morphine and DAMGO (a selective MOR
agonist) activated rat microglia and this activation was blocked
by the MOR-selective antagonist D-Phe-Cys-Tyr-D-Trp-Arg-
Thr-Pen-Thr-NH2 (CTAP) (15). Morphine increased Toll-like
Receptors (TLRs) expression which was attenuated by the MOR-
selective antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-
NH2 (CTOP). Additionally, thismorphine effect was abolished in
cultured microglia of MOR knockout (KO) mice (78). In murine
microglia, morphine increased the expression of cytokines and
activated the PKCe-Akt-ERK1/2 kinase pathway and these effects
were inhibited by Oprm1 RNA silencing as well as by CTAP
(14, 16). A low dose of morphine enhanced NF-kB activity
via MOR that was blocked by CTAP while a morphine high
dose triggered a TLR4-mediated non-opioid response (18). One
study has shown that, in vivo, the morphine-induced increase
in microglial P2X4R ATP-receptor was blocked by (-)-naloxone
but not by its (+)-naloxone enantiomer, implicating microglial
MOR rather than TLR4 in OIH (17). MOR implication in OIH
has been confirmed at the genetic level with the use of global
MOR KO mice (21, 79). Regarding the implication of TLR4
in OIH, the study of TLR4 KO mice has led to controversial
results as two papers showed that OIH was abolished in TLR4
KO mice while two others showed that it was maintained (6, 7).
Moreover, TLR4-independent activation of NF-kB by morphine
was shown together with increased Tumor Necrosis Factor alpha
(TNFα), suggesting TNFα signaling as a novel pathway for
morphine action on microglia (80). However, whether this effect
of morphine on microglia activation occurs directly through the
microglial MOR or indirectly via a neuronal MOR still remains to
be determined and could be addressed in upcoming studies such
as with conditional MOR-KO targeted at microglia or other cell
types.
The detection of Oprm1/OPRM1 in 27 out of 30 rodent
datasets and 16 out of 17 human whole genome transcriptomics
datasets issued from microglia ex vivo validates the presence
of MOR transcripts in microglia. From this analysis, we could
conclude that in the mammalian central nervous system,
microglia of the whole brain, cerebral cortex, hippocampus,
and spinal cord all contain Oprm1/OPRM1 messenger. Single-
cell RNA-seq currently allows detection of only a few thousand
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FIGURE 10 | MOR is expressed in mouse brain microglia. Photomicrographs from coronal sections of Frontal cortex (FCx), Nucleus Accumbens (NAcc), Central
Amygdala (CeA), Ventral Tegmental Area (VTA), and Periaqueductal Gray (PAG) of Cx3Cr1-eGFP-MOR-mCherry mice show the colocalization (orange) of
CX3CR1-eGFP (green), and MOR-mCherry (red) denoted by white arrows. Scale bar = 20µm.
of the most highly expressed transcripts within a specimen.
Therefore, this approach is used for determining differential gene
expression among the highly expressed genes and cannot analyze
complete transcriptomes (81). As Oprm1 is overall expressed
around or below the median within the reported transcriptomes,
the transcripts would not be contained among the few thousands
of highly expressed genes detected by single-cell RNA-seq studies.
This lack of expression is found also in theMars-seq datasets (58).
The analysis of the relationships between expression ofOprm1
and of the different gene clusters led to interesting insights. First,
Figures 5–9 show that the z-scores for Microglia-related gene
expression are globally above 1 while z-scores for neurons or
astrocytes were below 0, indicating a significant enrichment in
microglia compared to other cell types. The positive correlation
observed between Oprm1 and the Microglia module in mouse
cortex further supports the presence of Oprm1 expression in
microglia. Such a correlation was not found for the mouse
whole brain or spinal cord datasets, possibly reflecting the
diverse cellular heterogeneity in these tissues compared to a
defined region like the cortex. Indeed, the whole brain comprises
many distinct regions, and microglia from other brain regions
implicated in opioid response or pain, such as VTA, NAcc, or
PAG, should be further profiled at the molecular level in order to
characterize the global expression of microglialOprm1. Neurons,
GABAergic neurons and Astrocytes gene clusters correlate with
OPRM1 in the human cortex datasets but not in datasets
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FIGURE 11 | MOR is expressed in microglia of the mouse spinal cord. (A,B) Photomicrographs from transverse sections of the lumbar spinal cord, at the level of the
dorsal horn, demonstrate a colocalization (orange) of MOR-mCherry (red) with CX3CR1-eGFP-positive microglia (green) in adult male (A) and female (B)
Cx3Cr1-eGFP-MOR-mCherry mice, indicated by white arrow heads. Scale bar = 10µm. (C–E) High magnification photomicrographs of CX3CR1-eGFP positive
microglia (green) that colocalize (orange) with MOR-mCherry (red) are indicated with white arrows. Scale bar = 10µm. (C) Anti-GM130 labeling (blue) colocalizes
(pink-white) with MOR-mCherry in the cis-Golgi of CX3CR1-eGFP positive microglia, indicated with white arrows. (D) Anti-TGN38 labeling (blue) colocalizes
(pink-white) with MOR-mCherry in the trans-Golgi of CX3CR1-eGFP positive microglia, indicated with white arrows. (E) Anti-Lamp1 labeling (blue) of lysosomes does
not colocalize with MOR-mCherry in CX3CR1-eGFP positive microglia, indicated with open arrows. The white (closed) arrow indicate colocalization of CX3CR1-eGFP
with MOR-mCherry (orange) alone.
from rodents. A significantly higher content of neuronal and
astrocyte gene transcripts in FACS-isolated microglia compared
to cultured microglia has already been reported, and was
suggested to result from synapse-related mRNAs that were
phagocytosed by the microglia (19). The same phenomenon may
contribute to the positive correlation found between OPRM1
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and Neurons and Astrocytes modules in the human datasets,
despite their very low expression levels in the datasets. In addition
to the transcriptomic analysis, imaging of the Cx3cr1-eGFP-
MOR-mCherry reporter line confirmed MOR expression by
microglia of the FCx, NAcc, CeA, VTA, PAG, and spinal cord.
Furthermore, co-localization of microglial MOR with cis- and
trans-Golgi compartments but not lysosomes strongly supports
the protein synthesis and post-translational processing of MOR
within microglial cells.
Importantly, as discussed by Richard M Ransohoff, microglia
polarization into M1 and M2 subtypes appears too simplistic
and does not reflect the diversity of microglia phenotypes or
profiles induced by internal and external environmental factors
that include central nervous system region, sex, age, and health
state revealed by high-throughput analyses (82). Some reports on
microglia transcriptomics have defined co-regulated gene subsets
or modules to allow for classification of microglia into subtypes
expressing high levels of specific gene modules. We analyzed
the 47 microglia datasets and established three main activation
module profiles related to Interferon, LPS and Proliferation,
in relation to Oprm1 expression. We found a lack of, or a
poor correlation between Orpm1 and these modules. There
is a negative correlation between Oprm1 and the LPS-related
module in whole mouse brain datasets, and a positive correlation
between OPRM1 and the Proliferation-related module in human
cortex datasets. These low correlations may be explained by the
use of datasets from naive, non-stimulated rodents microglia
in which the LPS-related, Interferon-related, and Proliferation
related genes are expressed at the basal low level.
Several lines of evidence support a functional impact of MOR
on microglia activity. Morphine increased spinal microglial p38
and extracellular receptor kinase (ERK) phosphorylation, leading
to an augmented microglial production of proinflammatory
cytokines, and other pronociceptive molecules as well as their
receptors and hence to increased pain (15). Morphine also
enhances the activity of microglial ATP-gated P2X7R and P2X4R
receptors in the spinal cord, leading to increased Brain-derived
neurotrophic factor (BDNF) release from these cells. This
in turn downregulates K-Cl co-transporter KCC2 expression
in GABAergic neurons enhancing their excitability and thus
increased pain (8, 17, 20, 83). Other spinal microglial-mediated
responses for morphine analgesic tolerance and hyperalgesia
involve large conductance Ca2+-activated K+ channels (84) and
genes of the DPA12/TREM2 and potassium intermediate/small
conductance calcium activated channels KCNN4 pathways
(62). Furthermore, bidirectional cross-talks between chemokine
receptors and opioid receptorsmediate opioid analgesic tolerance
(85). Also, microglial pannexin-1 channels attenuate morphine
withdrawal in rodents but are not involved in opioid analgesic
tolerance, thus identifying pannexin-1 as a novel mediator of
specific morphine actions in microglia (86, 87). Peripheral nerve
injury leads to microglial activation in several brain structures
involved in pain sensation or emotion including the VTA and
amygdala (88). Within the VTA, chronic pain, chronic opiate
treatment, and opioid withdrawal induce a dysregulation of
BDNF in microglia that impacts on GABAergic neurons and
disrupts the dopaminergic pathway leading to defects in reward
(89, 90). Therefore, specific regulations in microglia appear
to mediate opioid reward and link chronic pain and opioid
dependence (91, 92) that may be mediated by MOR activity
within different subsets of microglia.
With the use of the Cx3cr1-eGFP-MOR-mCherry reporter
mouse, we have shown that, overall, 35–51% microglia express
MOR, suggesting that the receptor may be expressed by a
particular microglial subset and that only MOR-expressing
microglia will respond to opioid treatment. Future studies are
necessary to address how MOR expression within different
microglial subsets may impact on their functionality, under
physiological, and pathological conditions. The specific ablation
of the Oprm1 gene in the different subtypes of resting or activated
microglia by targeted Cre/Lox technology would require the
identification of unique and very selective gene markers for each
of these subtypes and the generation of the corresponding Cre
mouse lines. In the same line, optogenetic approaches allow the
evaluation of opioid signaling and behavior elicited by specific
spatiotemporal patterns of MOR activation in neurons (93) that
could be applied to microglia. Another aspect of MOR activation
is ligand-biased signaling where different ligands stimulate
differential cell responses (94, 95). We report an intracellular
localization of MOR within the Golgi apparatus of microglia
that suggests a local production of MOR in these cells. MOR
function in microglia could be investigated by novel biosensors
that have been assayed on transfected cell lines and primary
neuronal cultures, revealing a cell localization bias for opioid
receptor activation by endogenous, and exogenous opioids (96).
As sex differences are an important factor for microglial
contribution to pain (35, 36), we investigated MOR expression
in microglia from adult females and males. The transcriptomic
datasets did not contain enough numbers per sex for a full
determination of sex effect, see Figures 5–9. The analysis of brain
sections from the Cx3cr1-eGFP-MOR-mCherry mice indicated
a comparable ratio of microglia containing MOR in female
and male animals in different brain and spinal regions, except
in the VTA where significantly lower percentages of microglia
expressed MOR in females than males. It would therefore
be interesting to determine whether microglial MOR would
influence the regulatory mechanisms in the dopaminergic system
in females as has been previously described for males in the VTA
(89, 90). Also, sex differences in microglia activity were found
in the PAG where a significantly higher microglial activation
profile was found in females compared tomales (97). In the spinal
cord, the microglial P2X4R-mediated hyperalgesia showed sexual
dimorphism (98). Altogether this suggests that transcriptomic
profiles of microglia in chronic pain models or following
chronic drug administration may help to identify Oprm1-linked
mechanisms associated with alterations in microglial functions.
However, sex differences may exert a weaker influence on
morphine-induced analgesic tolerance and hyperalgesia than on
other forms of chronic pain like neuropathic pain. Indeed, these
morphine adverse effects occurred similarly in male and female
mice (79) and no clear impact was shown on OIH (6).
The question of the factors influencing the opioid effects on
microglia physiology should be further explored in the future
by taking into account the genetic diversity, sex differences, and
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pathological states (26). The importance of genetic background
on opioid tolerance, hyperalgesia (6), and misuse (99) has been
well-established in both clinical and preclinical settings. The
rodent datasets analyzed in the present study were from mouse
of C57BL/6 genetic background except four datasets issued from
other strains, genetic background, or species. In the future,
the study of Oprm1 expression may be broadened to a larger
number of rodent strains to get a more comprehensive view.
In addition, all human microglia datasets were collected from
cortical areas and there is a need for studies on microglia
from spinal cord and other brain regions involved in pain
and addiction. The correlations between rodent and human
transcriptomes may be studied as well. Galatro et al. have shown
an overlap between the two species, with similar microglia core
genes expressed by both human and mouse microglia including
the main markers CX3CR1, P2YR12, and Itgam. There were also
dissimilarities due to differences in environment and medical
condition as mouse microglia were isolated from healthy mice
while human donors suffered from pathologies that led to their
death, potentially influencing microglial genes regulation, and
expression (65).
Neuroinflammatory mechanisms underlie opioid-induced
pain sensitization (6, 7) comprising of reciprocal signaling
between neurons and neuroinflammatory cells including
microglia (100). OIH, together with abuse liability, contribute
to the opioid crisis that is epidemic in North America and
becoming prevalent in Europe as well (101). Therefore, the
elucidation of mechanisms involved in opioid deleterious
effects would help to develop new strategies for safer analgesic
clinical intervention. Altogether, this work on microglial Oprm1
expression and previous studies open the way to the exploration
of the role of microglial MOR in response to opiates, in particular
to analgesic tolerance, OIH, and physical dependence elicited by
their chronic use.
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